Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|January 25, 2012
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitusG Schernthaner, A H Barnett, A Emser, et al.
Diabetes, Obesity & Metabolism|June 16, 2011
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)U Graefe-Mody, C Friedrich, A Port, et al.
Diabetes, Obesity & Metabolism|November 27, 2014
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trialB Gallwitz, J Rosenstock, S Patel, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 26, 2015
Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetesS Durán-Garcia, J Lee, H Yki-Järvinen, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 1, 2007
Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humansH-J Woerle, M Albrecht, R Linke, et al.
Diabetes, Obesity & Metabolism|January 23, 2016
Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeksS Freude, T Heise, H-J Woerle, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 10, 2010
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetesT Forst, B Uhlig-Laske, A Ring, et al.
International Journal of Clinical Practice|June 14, 2012
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensionR Gomis, D R Owens, M-R Taskinen, et al.
Diabetes, Obesity & Metabolism|March 17, 2015
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitusE Araki, Y Tanizawa, Y Tanaka, et al.
Diabetes, Obesity & Metabolism|June 18, 2015
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)T R Pieber, S Famulla, J Eilbracht, et al.
Pageof 5